SCHEMBL4880879

SCHEMBL4880879

CC(C)(C)[Si](C)(C)OCCCN(C#N)c1ccc(NC(=O)c2nccnc2C(=O)Nc2ccc(Cl)cn2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.37
SMN1; SMN2 Q16637 6/20 0.37
NPC1 O15118 5/20 0.37
NFKB1 P19838 2/20 0.37
NFKB2 Q00653 2/20 0.37
RELA Q04206 2/20 0.37
LMNA P02545 2/20 0.37
ALDH1A1 P00352 1/20 0.37
CASP3 P42574 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
KMT2A Q03164 4/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
SIRT2 Q8IXJ6 3/20 0.35
TSHR P16473 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4881051 0.95 RAB9A (0.38) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL4878081 0.86 KMT2A (0.38) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL4881302 0.85 KMT2A (0.38) RAB9ASMN1; SMN2NPC1ALDH1A1KMT2A
SCHEMBL4875148 0.84 RAB9A (0.41) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL4885688 0.83 RAB9A (0.35) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL4710501 0.82 RAB9A (0.42) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL4876097 0.82 F10 (0.38) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL3614731 0.81 RAB9A (0.39) RAB9ASMN1; SMN2NPC1LMNAALDH1A1
SCHEMBL4881687 0.80 SIRT2 (0.37) RAB9ASMN1; SMN2NPC1LMNAALDH1A1
SCHEMBL4880731 0.78 MAPT (0.36) RAB9ASMN1; SMN2NPC1ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214533-A1 Cyclic Iminocarbamates And Their Use F2, UQCRB, F12 RAB9A 2655/4885SMN1; SMN2 2534/4885NPC1 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.